Company intelligence / Profile preview

Grupo Vanquish

Jiutepec, Morelos, Mexicogrupovanquish.com.mx ↗

Ownership: Private
Development stage: Commercial

Overview

No specific clinical trial phases reported; focus appears to be on marketed medicines, licensed medicines from suppliers, plus ongoing R&D. Emphasis is on product portfolio development targeting niche markets with unmet needs rather than clinical trial data disclosure.

Therapeutic areas: Infectious DiseasesEndocrinologyCardiovascularNeurologyWomen's Health
Modalities: Oral solid pharmaceutical products including effervescent formulationsActive pharmaceutical ingredientsMedical devices
Industry: Biotech

Drug pipeline

1 asset

calcium gluconolactate

Commercial

Indications: Osteoporosis

Partnerships

Collaborations via in-license agreements with international companies for medicine supply to Mexican public health institutions

Beyond the preview

Go deeper on Grupo Vanquish.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grupo Vanquish.

Explore the full profile